Evidence map›Paper›PMID 33785280›Full record

ArticleBrachytherapy

A multipurpose brachytherapy catheter to enable intratumoral injection.

Justin C Jagodinsky, Gabriella Medeiros, Hayley H Raj, Amira Razuan, Alexis Locsin, Tirhas G Dempsey, Beixiao Tang, Ishan Chakravarty, Paul A Clark, Raghava N Sriramaneni and 6 more

Open access · greenAbstract read
In one paragraph

Article in Brachytherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Iodine-125 plesiotherapy for murine tumor treatment.Radiation oncology (London, England) · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Justin C JagodinskyDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address: jagodinsky@wisc.edu.
Gabriella MedeirosDepartment of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI.
Hayley H RajDepartment of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI.
Amira RazuanDepartment of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI.
Alexis LocsinDepartment of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI.
Tirhas G DempseyDepartment of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI.
Beixiao TangDepartment of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI.
Ishan ChakravartyDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Paul A ClarkDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Raghava N SriramaneniDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Won Jong JinDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Keng-Hsueh LanDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Rupak K DasDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Jessica R MillerDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Darilis Suarez-GonzalezDepartment of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI YU, MENGGANG · 2016 to 2020
$10.8M
INTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3M
NRSA Training CoreTL1TR002375 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Vivek Prabhakaran · 2017 to 2026
$8.4M
Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9M
UW SPECT/CT AcquisitionS10OD028670 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI WEICHERT, JAMEY P · 2020 to 2020
$598k
Brachytherapy to achieve in situ cancer vaccinationF30CA250263 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI JAGODINSKY, JUSTIN CHARLES · 2021 to 2023
$96k
NCATS NIH HHS TL1 TR002375NCI NIH HHS F30 CA250263NCI NIH HHS P30 CA014520NIDCR NIH HHS P50 DE026787NIGMS NIH HHS T32 GM008692NIH HHS DP5 OD024576NIH HHS S10 OD028670
6 · The paper itself

Abstract

purposeTo create and test a multipurpose brachytherapy catheter prototype enabling intratumoral injection and brachytherapy after a single catheter insertion. METHODS AND MATERIALS: The design of the prototype consists of an outer tube and an inner syringe tube that can be filled with injectable agent. The outer sheath and inner syringe tube were constructed using polytetrafluoroethylene tubing, and the other components were 3D printed using dental resin and polylactic acid material. To demonstrate functionality, we injected in vitro phantoms with dyed saline. For proof of concept, we demonstrated the potential for the prototype to deliver cell therapy, enhance tumor delineation, deliver tattoo ink for pathology marking, avoid toxicity through local delivery of chemotherapy, and facilitate combination brachytherapy and immunotherapy.

resultsThe prototype enables accurate injection in vitro and in vivo without altering dosimetry. To illustrate the potential for delivery of cell therapies, we injected luciferase-expressing splenocytes and confirmed their delivery with bioluminescence imaging. To demonstrate feasibility of radiographically visualizing injected material, we delivered iohexol contrast intratumorally and confirmed tumor retention using Faxitron x-ray imaging. In addition, we show the potential of intratumoral administration to reduce toxicity associated with cyclophosphamide compared with systemic administration. To demonstrate feasibility, we treated tumor-bearing mice with brachytherapy (

conclusionsThese results demonstrate that a prototype multipurpose brachytherapy catheter enables accurate intratumoral injection and support the feasibility of combining intratumoral injection with brachytherapy.

Indexed as

BrachytherapyAnimalsCathetersHumansInjections, IntralesionalMicePhantoms, ImagingRadiometryBrachytherapyCell therapyContrast-enhanced imagingInterleukin 2Intratumoral injectionMultipurpose brachytherapy catheter

Identifiers

PMID33785280
PMCPMC8323107
OpenAlexW3151961468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.